Peptide Protocol
Peptide Protocol
 App Store

HGH Fragment 176-191: the complete guide

HGH Fragment 176-191 is a synthetic peptide corresponding to the C-terminal region of human growth hormone. It is studied for lipolytic effects without the IGF-1-raising or glucose effects of full-length HGH.

Written by Peptide Protocol Editorial Medically reviewed per our review process Last reviewed
ClassHGH C-terminal fragment
Half-lifeApproximately 30 minutes
Typical dose250–500 mcg, 1–3x daily subcutaneous
CategoryGrowth hormone axis / fat loss
Research useFat-loss research without full GH-axis activation
FDA statusNot FDA approved. Research use only in the US.

How HGH Fragment 176-191 works

The fragment is thought to stimulate beta-adrenergic lipolytic signaling in adipose tissue while lacking the full binding to the GH receptor, avoiding systemic GH-like metabolic effects. Much of the mechanism remains speculative in human data.

Typical HGH Fragment 176-191 dosage

Commonly reported research ranges: 250–500 mcg, 1–3x daily subcutaneous.

Dose should always be individualized. Factors that influence it include bodyweight, research goal, tolerance, and specific compound batch. The information below is educational, not a prescription.

How to reconstitute HGH Fragment 176-191

A widely used reconstitution for a 5 mg vial is 2 ml of bacteriostatic water. With a typical 500 mcg dose this works out to the unit count shown in the calculator below.

Open the HGH Fragment 176-191 reconstitution calculator →

Pre-filled with the common 5 mg + 2 ml ratio. Adjust for your own vial.

Half-life and administration frequency

Approximately 30 minutes.

This half-life informs how often HGH Fragment 176-191 is typically dosed. Shorter half-lives usually mean more frequent dosing to maintain plasma levels; longer half-lives allow daily, weekly, or less-frequent administration depending on the compound.

Reported side effects

This list reflects effects reported in available literature or user logs. It is not exhaustive. Adverse reactions should be discussed with a qualified clinician.

Common HGH Fragment 176-191 stacks

Storage and handling

Lyophilized: refrigerated. Reconstituted: refrigerated, use within 28 days.

FDA and regulatory status

Not FDA approved. Research use only in the US.

HGH Fragment 176-191 clinical trials and evidence

For clinical-trial and primary-literature context, start with the sources below. We prioritize official drug labels, ClinicalTrials.gov records, and PubMed-indexed literature when available.

Track your HGH Fragment 176-191 protocol on iPhone

Peptide Protocol logs every dose, calculates reconstitution for you, and keeps your full protocol on one calm screen.

See the app →

Frequently asked questions

What is HGH Fragment 176-191?

HGH Fragment 176-191 is a synthetic peptide corresponding to the C-terminal region of human growth hormone. It is studied for lipolytic effects without the IGF-1-raising or glucose effects of full-length HGH.

How does HGH Fragment 176-191 work?

The fragment is thought to stimulate beta-adrenergic lipolytic signaling in adipose tissue while lacking the full binding to the GH receptor, avoiding systemic GH-like metabolic effects. Much of the mechanism remains speculative in human data.

What is a typical HGH Fragment 176-191 dose?

Commonly reported ranges are 250–500 mcg, 1–3x daily subcutaneous. This is research information, not a recommendation — dosing should be individualized under clinical guidance.

What is the half-life of HGH Fragment 176-191?

Approximately 30 minutes. This influences how often it is administered.

How do you reconstitute HGH Fragment 176-191?

A common approach is to add 2 ml of bacteriostatic water to a 5 mg vial. Use the reconstitution calculator for exact unit counts.

What are the side effects of HGH Fragment 176-191?

Injection-site reactions; Headache (reported anecdotally); Transient fatigue; Limited long-term human data.

Is HGH Fragment 176-191 FDA approved?

Not FDA approved. Research use only in the US.

Are there clinical trials for HGH Fragment 176-191?

Registered or published clinical-trial sources for HGH Fragment 176-191 are listed in the references section below. Evidence depth varies widely by compound, so check the cited trial registries and primary literature before relying on any claim.

References

  1. HGH fragment 176-191 literature — National Library of Medicine. Primary research on the HGH C-terminal fragment lipolytic activity
  2. Ng et al. — Hyperphagia in hGH 176-191 transgenic models — PubMed. Preclinical characterization of the fragment
  3. AOD-9604 clinical trial records — ClinicalTrials.gov. Related AOD-9604 clinical studies

Sources listed above were used to verify the claims on this page. See our editorial policy for how we source information.

Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.